Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Electrocore LLC
NASDAQ ECOR
Data sourced from
and
and
Electrocore LLC Operating Income for the Trailing 12 Months (TTM) ending March 31, 2024: USD -16.90 M
Electrocore LLC Operating Income is USD -16.90 M for the Trailing 12 Months (TTM) ending March 31, 2024, a 28.05% change year over year. Operating Income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
-
Electrocore LLC Operating Income for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -23.49 M, a -16.05% change year over year.
-
Electrocore LLC Operating Income for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -20.24 M, a 8.49% change year over year.
-
Electrocore LLC Operating Income for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -22.12 M, a 44.55% change year over year.
-
Electrocore LLC Operating Income for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -39.89 M, a 33.14% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ECOR
| CEO | Mr. Daniel S. Goldberger |
| IPO Date | June 22, 2018 |
| Location | United States |
| Headquarters | 200 Forge Way, Rockaway, NJ, United States, 07866 |
| Employees | 68 |
| Sector | Healthcare |
| Industry | Medical devices |
Description
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Key trends
StockViz Staff
September 20, 2024
Any question? Send us an email